71 West Capital Partners Acquires New Position in Axon Enterprise, Inc $AXON

71 West Capital Partners acquired a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the fourth quarter, Holdings Channel reports. The firm acquired 1,224 shares of the biotechnology company’s stock, valued at approximately $695,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. NEOS Investment Management LLC raised its holdings in shares of Axon Enterprise by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after purchasing an additional 11,482 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Axon Enterprise by 1.3% in the 4th quarter. Legal & General Group Plc now owns 426,533 shares of the biotechnology company’s stock valued at $242,241,000 after purchasing an additional 5,419 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Axon Enterprise by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after purchasing an additional 376,904 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in shares of Axon Enterprise in the 4th quarter valued at about $13,116,000. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Axon Enterprise by 93.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,365 shares of the biotechnology company’s stock valued at $13,270,000 after purchasing an additional 11,262 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Up 0.3%

NASDAQ AXON opened at $443.21 on Tuesday. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. The firm has a market cap of $35.72 billion, a PE ratio of 178.00, a price-to-earnings-growth ratio of 8.03 and a beta of 1.45. The company has a 50 day moving average price of $410.95 and a 200 day moving average price of $488.34. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping the consensus estimate of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. Axon Enterprise’s revenue was up 33.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.47 EPS. As a group, sell-side analysts forecast that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CRO Cameron Brooks sold 1,242 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $621,000.00. Following the transaction, the executive owned 49,710 shares in the company, valued at approximately $24,855,000. This represents a 2.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 13,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the transaction, the president owned 169,125 shares in the company, valued at $82,609,106.25. The trade was a 7.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 38,989 shares of company stock worth $19,090,083 in the last three months. 4.20% of the stock is owned by company insiders.

Analyst Ratings Changes

AXON has been the subject of several recent research reports. Wall Street Zen upgraded shares of Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Citigroup restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, February 25th. Robert W. Baird set a $800.00 price target on shares of Axon Enterprise in a report on Wednesday, February 25th. Zacks Research upgraded shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Finally, Needham & Company LLC reduced their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and a consensus target price of $712.75.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.